NCT01952249View on ClinicalTrials.gov

A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian

PHASE1TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 5, 2013

Primary Completion Date

May 10, 2016

Study Completion Date

July 12, 2016

Conditions
Primary Peritoneal Carcinoma
Interventions
DRUG

Demcizumab

administered intravenously

DRUG

Taxol

administered intravenously

Trial Locations (3)

19104

University of Pennsylvania, Philadelphia

73104

University of Oklahoma Stephenson Cancer Center, Oklahoma City

77030

The University of Texas MD Anderson Cancer Center Department of Gynecologic Oncology, Houston

Sponsors
All Listed Sponsors
lead

OncoMed Pharmaceuticals, Inc.

INDUSTRY

NCT01952249 - A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian | Biotech Hunter | Biotech Hunter